Screener
Krystal Biotech, Inc. KRYS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Foreign currency translation | (1,182) | 236 |
| Comprehensive income | $53,173 | $36,313 |
| Net income per common share: | ||
| Basic | $1.91 | $1.24 |
| Diluted | $1.83 | $1.20 |
| Weighted-average common shares outstanding: | ||
| Basic | 29,288 | 28,815 |
| Diluted | 30,507 | 29,871 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s EPS (diluted)?
- Krystal Biotech, Inc. (KRYS) reported EPS (diluted) of $1.83 in Q1 2026.
- How has Krystal Biotech, Inc.'s EPS (diluted) changed year-over-year?
- Krystal Biotech, Inc.'s EPS (diluted) increased by 52.5% year-over-year, from $1.20 to $1.83.
- What is the long-term trend for Krystal Biotech, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s EPS (diluted) has grown at a 21.6% compound annual growth rate (CAGR), from -$3.13 to $6.85.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Krystal Biotech, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude